#1 Clinical Trials Search in Europe

Vanglusagene Ensiparvovec

Vanglusagene Ensiparvovec, also known as SPK-3006, is an investigational gene therapy being studied for the treatment of Late-Onset Pompe Disease (LOPD). This article discusses the ongoing clinical trials evaluating the safety, tolerability, and potential efficacy of this novel therapy in adult patients with LOPD. We’ll explore the key aspects of the trial, including its objectives, eligibility criteria, and expected outcomes.

Table of Contents

What is VANGLUSAGENE ENSIPARVOVEC?

VANGLUSAGENE ENSIPARVOVEC, also known as SPK-3006, is an innovative gene therapy being developed to treat Late-Onset Pompe Disease (LOPD)[1]. It is classified as an orphan drug, which means it is intended to treat a rare disease[1]. This therapy is currently undergoing clinical trials to evaluate its safety and effectiveness in patients with LOPD.

VANGLUSAGENE ENSIPARVOVEC is a recombinant adeno-associated viral vector that contains a specially designed genetic material. This genetic material is intended to produce a secretable form of human acid alpha-glucosidase (GAA), an enzyme that is deficient in people with Pompe disease[1].

Target Condition: Late-Onset Pompe Disease

VANGLUSAGENE ENSIPARVOVEC is designed to treat Late-Onset Pompe Disease (LOPD), also known as glycogen storage disease type II[1]. Pompe disease is a rare genetic disorder characterized by the buildup of a complex sugar called glycogen in the body’s cells. This accumulation affects various body tissues and organs, particularly the muscles, leading to progressive muscle weakness.

In LOPD, symptoms typically appear later in childhood, adolescence, or adulthood. These may include:

  • Progressive muscle weakness, especially in the legs and trunk
  • Breathing problems, particularly when lying down
  • Fatigue
  • Difficulty walking or climbing stairs

How VANGLUSAGENE ENSIPARVOVEC Works

VANGLUSAGENE ENSIPARVOVEC is a gene therapy that aims to address the underlying cause of Pompe disease. Here’s how it works:

  1. The therapy uses a modified virus (adeno-associated virus) as a vehicle to deliver a functional copy of the GAA gene to the patient’s cells.
  2. This gene contains instructions for producing the GAA enzyme, which is lacking in people with Pompe disease.
  3. Once inside the cells, the gene should lead to the production of functional GAA enzyme.
  4. The therapy is designed to produce a secretable form of GAA, which means the enzyme can be released from cells and potentially taken up by other cells in the body.

By increasing the levels of functional GAA enzyme in the body, VANGLUSAGENE ENSIPARVOVEC aims to reduce the accumulation of glycogen in cells and alleviate the symptoms of Pompe disease[1].

Current Clinical Trial

VANGLUSAGENE ENSIPARVOVEC is currently being studied in a Phase 1/2 clinical trial. This trial is designed to evaluate the safety, tolerability, and potential efficacy of a single intravenous infusion of the therapy in adults with late-onset Pompe disease[1].

Key aspects of the trial include:

  • It is a dose-escalation study, meaning different dose levels will be tested to find the optimal dose.
  • The therapy is administered as a single intravenous infusion.
  • Participants will be adults (18 years and older) with confirmed LOPD.
  • The study aims to include patients with moderately advanced disease who can still walk at least 75 meters but less than 500 meters in a 6-minute walk test.

Eligibility Criteria

To participate in the clinical trial, patients must meet specific criteria. Some key eligibility factors include[1]:

  • Confirmed diagnosis of LOPD
  • Age 18 years or older
  • Have been receiving enzyme replacement therapy (ERT) for at least 24 months
  • Able to walk between 75 and 500 meters in a 6-minute walk test
  • Have a forced vital capacity (a measure of lung function) between 30% and 80% of predicted value

There are also several exclusion criteria, such as prior gene therapy treatment, active infections, significant liver disease, and others. It’s important to note that eligibility is determined by healthcare professionals based on a comprehensive evaluation[1].

Safety and Efficacy Evaluation

The primary focus of the current clinical trial is to assess the safety and tolerability of VANGLUSAGENE ENSIPARVOVEC. Researchers will be monitoring[1]:

  • Adverse events and serious adverse events
  • Changes in laboratory values, vital signs, and physical examinations
  • Immune responses against the therapy
  • Liver function tests

To evaluate the potential efficacy of the treatment, the study will measure[1]:

  • Changes in the distance walked in the 6-minute walk test
  • Changes in forced vital capacity (a measure of lung function)
  • Levels of GAA enzyme in the blood
  • Biomarkers of muscle injury and glycogen accumulation

Potential Benefits

While it’s important to note that VANGLUSAGENE ENSIPARVOVEC is still in the experimental stage, it has the potential to offer several benefits for people with LOPD[1]:

  • Long-lasting treatment: As a gene therapy, it may provide a long-term solution with a single treatment, unlike current enzyme replacement therapies that require regular infusions.
  • Improved muscle function: By addressing the underlying cause of the disease, it may help improve muscle strength and function.
  • Enhanced quality of life: If successful, it could significantly improve the daily lives of people with LOPD by reducing symptoms and slowing disease progression.
  • Reduced treatment burden: A one-time treatment could eliminate the need for frequent hospital visits for enzyme replacement therapy.

It’s crucial to remember that these potential benefits are still being investigated in clinical trials, and more research is needed to confirm the safety and efficacy of VANGLUSAGENE ENSIPARVOVEC[1].

Aspect Details
Drug Name Vanglusagene Ensiparvovec (SPK-3006)
Trial Phase Phase 1/2
Condition Late-Onset Pompe Disease (LOPD)
Administration Single intravenous infusion
Primary Objectives Evaluate safety and tolerability
Secondary Objectives Evaluate potential efficacy and bioactivity
Key Inclusion Criteria Adults ≥18 years, confirmed LOPD diagnosis, stable ERT for 24 months
Key Exclusion Criteria Prior gene therapy, active infections, significant liver disease
Primary Endpoints Adverse events, laboratory values, immune responses
Secondary Endpoints Changes in 6MWT, FVC, GAA enzyme levels, biomarkers

FAQ

  • What is Vanglusagene Ensiparvovec? Vanglusagene Ensiparvovec, also known as SPK-3006, is an investigational gene therapy designed to treat Late-Onset Pompe Disease (LOPD). It is a recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimized expression cassette to drive the expression of a secretable form of human acid alpha-glucosidase (GAA).
  • What is the main objective of the clinical trial for Vanglusagene Ensiparvovec? The main objective of the clinical trial is to evaluate the safety and tolerability of a single intravenous dose of Vanglusagene Ensiparvovec administered at escalating dose levels to participants with clinically moderate Late-Onset Pompe Disease (LOPD).
  • Who is eligible to participate in the Vanglusagene Ensiparvovec clinical trial? Eligible participants are adults (18 years or older) with a confirmed diagnosis of Late-Onset Pompe Disease (LOPD) who have been receiving a marketed enzyme replacement therapy (ERT) for at least 24 months. They must have clinically moderate LOPD characteristics, including the ability to walk between 75 and 500 meters on the 6-minute walk test and have a predicted forced vital capacity between 30% and 80% in the upright position.
  • What are some of the key exclusion criteria for the trial? Key exclusion criteria include active hepatitis B or C, prior gene therapy treatment, significant underlying liver disease, HIV infection, and high antibody responses to recombinant human GAA. Participants must also not have received live vaccines within 30 days prior to informed consent or plan to receive them within 52 weeks after the SPK-3006 infusion.
  • What are the primary endpoints of the Vanglusagene Ensiparvovec clinical trial? The primary endpoints of the trial include the incidence of adverse events and serious adverse events, changes in laboratory values, vital signs, and physical examinations, vector shedding in bodily fluids, liver function tests, and immune responses against the AAV-Spark100 capsid and GAA transgene product.

Ongoing Clinical Trials on Vanglusagene Ensiparvovec

  • Study on the Safety and Effects of SPK-3006 for Adults with Late-Onset Pompe Disease

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Pompe Disease: Also known as glycogen storage disease type II, Pompe Disease is a rare genetic disorder characterized by the buildup of glycogen in cells, which impairs the function of different organs and tissues, especially muscles.
  • Late-Onset Pompe Disease (LOPD): A form of Pompe Disease that appears later in childhood, adolescence, or adulthood. It typically progresses more slowly than the infantile-onset form.
  • Vanglusagene Ensiparvovec (SPK-3006): An investigational gene therapy designed to treat Late-Onset Pompe Disease by delivering a functional copy of the GAA gene to cells.
  • Enzyme Replacement Therapy (ERT): A treatment approach that involves administering functional enzymes to patients with enzyme deficiencies, such as in Pompe Disease.
  • Six-Minute Walk Test (6MWT): A clinical test that measures the distance an individual can walk on a flat, hard surface in six minutes, used to assess functional capacity.
  • Forced Vital Capacity (FVC): The total amount of air exhaled during a forced breath, used to assess lung function.
  • Adeno-Associated Viral Vector (AAV): A virus-based vehicle used to deliver genetic material into cells for gene therapy purposes.
  • Acid Alpha-Glucosidase (GAA): An enzyme responsible for breaking down glycogen in lysosomes. Mutations in the GAA gene cause Pompe Disease.
  • Neutralizing Antibody (NAb): Antibodies that defend against pathogens or foreign substances by neutralizing their biological effects.
  • Vector Shedding: The release of viral vectors used in gene therapy from the body through various bodily fluids.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-spk-3006-for-adults-with-late-onset-pompe-disease/